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Trends
Although alternative splicing is well
documented at the transcript level,
large-scale proteomics experiments
identify few alternative isoforms.
Proteomics evidence also suggests
that the vast majority of genes have a
single dominant splice isoform.
Alternative isoforms detected in proteo-
mics experiments tend to be conserved,
are highly enriched in subtle splice
events such as mutually exclusively
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Alternative splicing is commonly believed to be a major source of cellular
protein diversity. However, although many thousands of alternatively spliced
transcripts are routinely detected inRNA-seq studies, reliable large-scalemass
spectrometry-based proteomics [13_TD$DIFF]analyses identify only a small fraction of
annotated alternative isoforms. The clearest ﬁnding from proteomics experi-
ments is thatmost humangenes have a singlemain protein isoform,while those
alternative isoforms that are identiﬁed tend to be the most biologically plausi-
ble: those with the most cross-species conservation and those that do not
compromise functional domains. Indeed, most alternative exons do not seem
to be under selective pressure, suggesting that a large majority of predicted
alternative transcripts may not even be translated into proteins.spliced homologous exons and events
that do not disrupt functional domains.
Recent large-scale RNA-seq studies
have shown that tissue speciﬁcity
seems to be controlled by gene expres-
sion rather than alternative splicing.
Variant calling experiments show that
most alternative exons are evolving
neutrally, which suggests that most
alternative splice events are not evolu-
tionary innovations.
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(A. Valencia).One Gene, One Protein or One Gene, Many Proteins?
Alternative splicing of messenger RNA produces a wide variety of differently spliced RNA
transcripts that may be translated into diverse protein products. The presence of alternatively
spliced transcripts is unequivocally supported by expressed sequence tag and cDNA sequence
evidence [1], microarray data [2], and RNA-seq data [3,4]. It has been estimated that most
multiexon human genes can undergo alternative splicing [5].
Manual genome annotation projects [1,6,7] have added substantial numbers of alternatively
spliced transcripts to reference databases in recent years; the current version of the GENCODE
human gene set (v24) [1] contains 82 141 coding sequence (CDS) distinct protein-coding
transcripts. Many estimates for the number of transcripts expressed in human cells are even
higher; a recent large-scale RNA-seq analysis [3] found multiple splice variants for 72% of
annotated human genes, while another predicted that 205 000 transcripts had protein-coding
potential, which would mean more than ten variants per annotated gene [8].
The breadth of alternative splicing detectable at the transcript level has led to claims that
alternative protein isoforms could be the key to mammalian complexity [9]. How much of this
alternative splicing is functional at the protein level is a long-standing open question of great
importance for understanding eukaryotic biology (Box 1).
Alternative Splice Isoforms
From the protein point of view there are two broad classes of alternative splicing: those that result
in insertions or deletions (indels) and those that result in exon substitutions (Figure 1). The
majority of annotated splice events involve the loss or gain of exons, or parts of exons [23]. These
splice events generate alternative proteins with indels of widely different sizes as long as they doTrends in Biochemical Sciences, Month Year, Vol. xx, No. yy http://dx.doi.org/10.1016/j.tibs.2016.08.008 1
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Box 1. The Role of Alternative Isoforms
The functional role of alternative protein isoforms has been the subject of considerable debate. One strongly supported
theory is that alternative splicing exists to allow the tissue-speciﬁc rewiring of protein–protein interaction networks [10,11].
This hypothesis is based on the tissue-speciﬁc expression of alternative transcripts, the loss of functional domains, and
the prevalence of disordered protein regions in alternative isoforms [12]. At the other extreme, it has been suggested that
stochastic models explain alternative splicing and that most alternative transcripts will not code for proteins [13].
Although there are 26 000 publications with the phrase ‘alternative splicing’ in PubMed, very few alternative protein
isoforms have well-characterized cellular function. The difﬁculty of determining molecular function means that even when
alternative transcripts are found in tissues, what we know about their cellular role is incomplete [14,15]. A review of the
role of more than 250 alternative isoforms [16] found that most alternative isoforms either sort into different cellular
compartments or have a net negative effect on the function of the reference isoform. The review included 15 examples of
modulation of function brought about by homologous exon substitution. In general, the conclusion was that changes
brought about by alterative splicing were hard to detect.
A major large-scale yeast two-hybrid experiment with cloned alternative isoforms came to a contrasting conclusion. The
authors found large functional differences between reference and alternative isoforms and showed that many alternative
isoforms would indeed interact with different protein partners in vitro [17], in support of the tissue-speciﬁc rewiring
hypothesis. This contrasting result was almost certainly due to the fact that 70% of the [9_TD$DIFF] expressed alternative isoforms[1_TD$DIFF]
had lost more than 60 residues, greatly increasing the chances of affecting protein domains and impacting reference
interactions.
Large-scale RNA-seq experiments have shown that gene expression levels have strong tissue dependence that is
conserved across both individuals [16] and different species [18]. However, alternative splicing levels are not conserved.
For example, the GTex Consortium found that 84% of the variance between human tissues was due to gene expression,
while splicing variation was much more pronounced between individuals [19], leading them to conclude that much
alternative splicing is stochastic. Alternative exon usage also varies more between species [20,21] than it does between
tissues. Meanwhile, Reyes et al. [22] found that a ‘sizeable minority’ of exons, enriched in exons from 30 and 50
untranslated regions, had expression that was strongly tissue speciﬁc across species.not cause a shift in the reading frame. Another common splice event is the substitution of one or
more exons; this happens most often at the 30 and 50 ends of the transcripts [23,24]. Most of the
resulting alternative proteins will have completely different N- or C-terminal sequences (Figure 1).
However, a small proportion of these substituted exons have detectable homology, andmutually
exclusive splicing of these exons [24,25] will result in alternative homologous protein sequences
(Figure 1).
Proteomics Experiments Find Little Evidence of Alternatively Spliced
Proteins
Recent advances have made tandem mass spectrometry-based proteomics experiments an
increasingly important tool for validating the translation of protein-coding genes [26,27] and
large-scale mass spectroscopy experiments are now the main source of evidence of alternative
splicing at the protein level.
We recently carried out a reanalysis of the peptides and spectra from eight large-scale experi-
ments and databases [24]. In order to generate as reliable a set of peptides as possible we
implemented a series of stringent ﬁlters (Box 2). The rigorous quality controls allowed us to
be conﬁdent that the vast majority of identiﬁed peptides and splice events were present in the
individual studies. While relaxing quality controls would have allowed us to detect more
alternative peptides, it would also have increased the proportion of false-positive identiﬁcations
based on marginally valid peptide spectrum evidence (Box 3).
After applying these stringent ﬁlters, we still found peptides for the majority of protein-coding
genes (12 716), but few genes (246) had reliable evidence for more than one isoform. This
strongly suggests that alternative variants are not abundant at the protein level. The low number
of protein splice isoforms is in stark contrast to the abundance of alternative transcripts in2 Trends in Biochemical Sciences, Month Year, Vol. xx, No. yy
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Figure 1. Types of Alternative Isoforms. This ﬁgure presents three types of alternative variants deﬁned using the gene SLC25A3, a mitochondrial phosphate carrier
protein. In each case, we show the effect at the transcript level and at the protein level. (A) Homologous exons. Above, schema of variant [6_TD$DIFF]SLC25A3-005, which is
generated from variant [6_TD$DIFF]SLC25A3-001 via the substitution of exon 2a (black) by exon 2b (orange). The differing protein sequences are shown in the alignment below
the transcript level comparison. Middle, example spectra for the two peptides that identify the two different alternative isoforms. Below, the likely effect on protein structure
(shown in two views) for the similar gene SLC25A4 (PDB code: 1okc); residues that differ between the two isoforms are shown as orange sticks. The change to the
structure and function is likely to be comparatively subtle: no residues are lost and most of the changes are found on the outside of the pore. (B) Nonhomologous
substitution. Above, schema of variant [6_TD$DIFF]SLC25A3-015, which is generated from variant [6_TD$DIFF]SLC25A3-001 via the substitution of exon 3 (the longer alternative exon is in red).
Below, the likely effect on protein structure shown in two different views; residues that would be lost in the alternative isoforms are shown in red. (C) Insertions or deletions
(Indels). Above, schema of variant [6_TD$DIFF]SLC25A3-002, which is generated from variant [6_TD$DIFF]SLC25A3-001 via the skipping of exon 6 (green). Below, the likely structural effect of this
loss of 28 amino acids is shown in two different views; residues that would be lost in the alternative isoforms are shown in green. The deletion would remove the base of
the pore and parts of two different trans-membrane helices meaning that the trans-membrane sections would have to completely refold. Images generated with the
PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC.microarray and RNA-seq experiments and is especially surprising in light of the fact that the eight
large-scale experiments interrogated more than 100 different tissues, cell lines, and develop-
mental stages [24].
We carried out simulations to test whether the number was smaller than expected (Box 4).
Simulations that assumed that all isoforms in a gene were equally likely detected alternative
isoforms for over 3500 genes, while we found alternative splicing for more than 1250 genes in
simulations where reference isoforms were 50 times[3_TD$DIFF] abundant [14_TD$DIFF] than alternative isoforms.
Almost All Coding Genes Seem to Have a Main Protein Isoform
The question of whether or not genes have dominant variants has become increasingly
important as the numbers of annotated transcripts have grown. Large-scale transcriptomicsTrends in Biochemical Sciences, Month Year, Vol. xx, No. yy 3
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Box 2. Stringent Filters on Large-Scale Proteomics Data Improve Reliability
The numbers of alternative splice events reported by large-scale proteomics experiments vary by many orders of
magnitude [28–33]. However, those experiments with the highest numbers of alternative splice isoforms overestimate the
number of alternative proteins [24]. Alternative isoforms should only be identiﬁed when peptides map to both sides of a
splicing event (Figure I), but many studies report alternative isoforms when peptides identify just one of the two splice
isoforms.
Other large-scale proteomics experiments correctly identify splice isoforms [29,30], but then substantially underestimate
the false-positive rates of their experiments [34,35]. High false-positive rates will artiﬁcially inﬂate the number of alternative
isoforms detected; 11% of the theoretical peptides from the human reference annotation [1] map to alternative isoforms,
so one in every nine false-positive peptide matches will ‘identify’ a peptide that maps to an alternative isoform.
In our study, we brought together peptides from eight large-scale studies. Combining many sources of data comes at a
cost [26,35], so it is vital to control false-positive rates. We implemented a series of stringent ﬁlters on the eight individual
experiments to remove as many false-positive peptides as possible [24,36].
Where two or more search engines were used to detect peptides, we required that at least two search engines agreed on
the peptide identiﬁed in each spectrum. All nontryptic and semitryptic peptides were ﬁltered out and missed cleavages
were allowed only when they were also supported by one of the fully cleaved tryptic peptides. Residues identiﬁed as
leucine or isoleucine were allowed to map to both leucine and isoleucine in the GENCODE20 gene set. Peptides that
mapped to more than one gene were removed.
We removed all peptides that were only identiﬁed in one of the eight studies. While some peptides that appear in a single
study may be tissue speciﬁc, or detected in just one study for technical reasons, peptides that are identiﬁed in just
one experiment are also highly enriched in false-positive identiﬁcations [35]. In this experiment, we chose to sacriﬁce
coverage for reliability. In order to detect a biological signal, we ﬁrst had to remove as much noise as possible. Further
details can be found in Abascal et al. [24] and Ezkurdia et al. [36].
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Figure I. Identifying Alternative Splice Events. Part of an alignment between two splice isoforms of the gene EEF1D.
Identiﬁed peptides are in red font and vertical lines mark the position of exon boundaries. The two regions that distinguish
the isoforms are marked as A and B and the extent of the differences between the two regions is marked by a blue line.
Region A differs by an insertion or deletion (indel); peptides that map to both sides of the indel conﬁrm the translation of
this splice isoform. By contrast, peptides map to just one side of the splice event in region B (a C-terminal substitution), so
the translation of an alternative isoform with the alternative C terminus is not conﬁrmed.studies [38–40] have shown that genes have dominant transcripts, even if a proportion of them
are noncoding or subject to nonsense-mediated decay [38]. Most genes have a single dominant
transcript across all cell lines [38,39], but as many as a third of genes have tissue-dependent
dominant transcripts [40].
By contrast, proteomics studies strongly suggest that most genes have a single main protein
isoform; 99.63%of the peptideswedetectedmapped to [15_TD$DIFF]the [16_TD$DIFF]reference isoform [17_TD$DIFF]for each gene [24].
This evidence motivated us to determine a ‘main’ experimental isoform. We summed up the
peptides detected for each isoform across the eight studies and the unique CDS with the most4 Trends in Biochemical Sciences, Month Year, Vol. xx, No. yy
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compared these with known reference variants [36].
‘Dominant’ RNA-seq transcripts are those that are expressed at least ﬁvefold more than other
transcripts across all tissues or cell lines [38]. We found that the agreement between dominant
variants from the two experimental procedures was just 77–78% (Figure 2). The main reason for
the disagreement is likely to be technical rather than biological: transcript reconstruction from
short RNA-seq reads is a complex problem and algorithms for reconstructing and quantifying
full-length mRNA transcripts are inaccurate [41].
The longest isoform is chosen as the reference isoform for technical reasons in practically all
studies and databases. Although it has no biological basis, the longest isoform still agreed with
themain experimental proteomics isoform across 89.6% of genes (Figure 2), suggesting that this
is a reasonable but far from perfect strategy.
Consensus coding DNA sequence (CCDS) variants [42] are transcript models agreed on by
independent teams of manual annotators using genomic evidence including the presence of
cDNAs. When there is just one CCDS variant per gene, these can be used as a proxy for the
reference variant. The agreement between the main experimental isoforms and unique CCDS
variants was an impressive 98.6%.
In addition to the experiment-based methods, there are also two recently developed computa-
tional methods that predict reference isoforms. Highest connected isoforms [43] predict
reference isoforms based on transcript expression data, amino acid composition, and pro-
tein–protein docking. APPRIS [37] determines ‘principal’ isoforms using cross-species conser-
vation and the conservation of protein structure and functional features. The agreement betweenBox 3. The Difﬁculty of Correctly Identifying Peptide-Spectrum Matches
It is easy to misidentify peptides in proteomics experiments (Figure I). Here two similar peptides with the same amino acid
composition and molecular weight (AQLEQLTTK and QALQELTTK) were identiﬁed from a single spectrum during a
reanalysis of the Kim et al. [29] experiment (Figure [10_TD$DIFF] ). This was not an isolated spectrum; many of the spectra from Kim
et al. analysis retina samples did not have enough information for search engines to distinguish one peptide from the
other. While peptide AQLEQLTTK is from retinaldehyde-binding protein 1 (RLBP1), a retina-speciﬁc protein for which
80% of the sequence was identiﬁed by peptides found in retina samples, the peptide QALQELTTK maps to BLOC1S6, a
gene that the Kim et al. analysis places almost entirely in hematopoietic cells. We did not identify QALQELTTK in any
tissue other than retina.
The spectrum can only belong to one of the two peptides and AQLEQLTTK clearly ﬁts the tissue speciﬁcity of the
experiments much better than QALQELTTK. Further support for peptide AQLEQLTTK comes from the reliable Pepti-
deAtlas database [24] where the peptide has been identiﬁed 51 times, all in retina-speciﬁc experiments. QALQELTTK has
never previously been identiﬁed in PeptideAtlas.
Search engines performing the reanalysis identiﬁed AQLEQLTTK 85 times and the peptide QALQELTTK nine times in
spectra from retina samples. Given the tissue speciﬁcity of BLOC1S6, this is nine times too many, and to make matters
worse the identiﬁcation of QALQELTTK was determined to be signiﬁcant in three cases. This is important because
QALQELTTK would be used to identify an alternative isoform of BLOC1S6. In large-scale analyses, researchers cannot
carry out similar in-depth investigations into all peptides and spectra, so the BLOC1S6 alternative variant would be
identiﬁed as being expressed in retina. This isoform was not detected in our pipeline because of the rigorous quality
controls we had in place.
This case is based on the misidentiﬁcation of a good spectrum with multiple assigned peaks. If the spectra are poor or if
the peptide identiﬁcations are borderline, the chances of misidentiﬁcation will multiply. Post-translational modiﬁcations
complicate the identiﬁcations still further; if post-translational modiﬁcations are taken into account, correctly identifying
peptide-spectrum matches becomes even more complex [24]. These problems complicate the identiﬁcation of novel
coding regions and alternative isoforms in large-scale proteomics studies [35] and are currently not being addressed.
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Figure I. Identifying Two Peptides from the Same Spectrum. (A) The peptide AQLEQLTTK is from the main
isoform of RLBP1 (retinaldehyde-binding protein 1), a protein expressed in retina. The structure of RLBP1 has been
resolved and is shown bottom right; the position of peptide AQLEQLTTK is marked in blue. (B) Peptide QALQELTTK
supports the presence of an alternative isoform of BLOC1S6 that would cause the loss of the large coiled coil region
shown in gray in the ﬁgure. [8_TD$DIFF] Abbreviation: Mol weight, molecular weight.the highest connected isoforms and the main experimental isoforms was just 78% (Figure 2).
By contrast, the APPRIS principal isoforms coincided with the main experimental isoform over
97.6% of comparable genes.
Remarkably, the agreement between the main proteomics isoform, the APPRIS principal
isoforms, and the unique CCDS variants was almost perfect (99.4%) over the 3015 genes
where all three methods had a single reference isoform [38]. The fact that three entirely
orthogonal sources of reference isoforms have such an outstanding agreement highlights the
biological signiﬁcance of the results from the proteomics experiments and signiﬁcantly
reinforces the likelihood that the main proteomics isoform is the dominant protein isoform
in the cell.6 Trends in Biochemical Sciences, Month Year, Vol. xx, No. yy
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Figure 2. Coincidence between Main Proteomics Isoforms and Other Reference Isoforms. The percentage of
genes in which there was agreement between the reference isoform for a gene and the main proteomics isoform calculated
from the proteomics experiments [36]. The comparison was made over all 5011 genes from the same proteomics study for
the longest isoform, over a subset of 3331 genes with consensus coding DNA sequence (CCDS)-unique isoforms [42] for
the CCDS comparison, over a subset of 4186 genes with principal isoforms for the APPRIS comparison [37], and over a
subset of 1038 genes with ﬁvefold dominant transcripts across all tissues for the RNA-seq comparison [38]. The highest
connected isoform comparison was made using data from the paper that introduced the method [43]. A random selection
of isoforms would have agreed with the main proteomics isoform 46% of the time.Detected Splice Events Have Comparatively Subtle Effects on the Protein
Standard mass spectrometry proteomics experiments only identify a proportion of the peptide
ions present in protease digests [44]. The peptide coverage for highly expressed proteins is
rarely complete and proteins expressed in low quantities are often not detected at all [44]. This
means that alternative splice isoforms present in low quantities in the cell may not be picked upBox 4. Estimating the Expected Number of Alternative Splice Isoforms
We estimated the numbers of alternative splice isoforms we would expect to detect in the experiments via simulations.
For the ﬁrst simulation, we assumed that all transcripts were expressed equally. We carried out an in silico lysis of
the GENCODE20 database [1] to produce tryptic peptides and selected at random the same number of peptides for
each gene as were identiﬁed in the experiments. We mapped these peptides to the database, repeated the experiment
100 times and took the average values.
If we had only used tryptic peptides in our analysis, we would have found alternative splicing for 226 genes instead of
246 (20 splice isoforms were identiﬁed via missed cleavages), and 14 genes would have had evidence of two or more
alternative isoforms.
By contrast, the numbers from the in silico analysis were substantially larger. We identiﬁed alternative splicing for
3508 genes (15.5 times greater than the experiments), and two or more alternative isoforms for 937 genes (67 times
greater than the experiments). This clearly suggests that one protein isoform per gene is dominant.
We repeated the experiment simulating a model where one isoform had 50-fold dominance over the other isoforms. We
generated 50 times more peptides for the principal isoform of each gene via the in silico lysis (principal isoforms taken
from the APPRIS database [37]) and repeated the simulation with this larger database. This time the peptides identiﬁed
1289 genes with evidence of alternative isoforms and 152 genes with two or more alternative isoforms. The numbers
from the 50-fold dominant model are still much larger than the experiments, implying that alternative isoforms are
expressed at amuch lower level than themain isoforms. The simulations demonstrate that we ought to detect manymore
alternative isoforms than we did, so the lack of alternative isoforms in the experiments is not solely the result of poor
coverage.
In fact, the proteomics experiments also ﬁndmany fewer alternative peptides than expected. While more than 11% of the
tryptic peptides from GENCODE20 map to alternative isoforms, alternative peptides [11_TD$DIFF]were just 0.376% of the peptides
identiﬁed in proteomics experiments.
Trends in Biochemical Sciences, Month Year, Vol. xx, No. yy 7
TIBS 1293 No. of Pages 13by proteomics experiments, which could partly explain why so few alternative isoforms are
detected in proteomics experiments.
It is also possible that the low numbers of alternative peptides are in part due to limited sampling
depth. Although the combined large-scale experiments covered more than 100 tissues and
developmental stages, the low coverage typical of proteomics experiments would make tissue-
speciﬁc splice isoforms harder to detect.
Despite these technical issues, the patterns evident in the set of alternative isoforms identiﬁed in
the proteomics experiments clearly show that some alternative variants are more important than
others [4_TD$DIFF]. These patterns are further strong indications that limited sampling depth and low
coverage are not the only reason for not ﬁnding larger numbers of alternative peptides (Box 4).
Alternative splice isoforms identiﬁed in the experiments were highly enriched in duplicated
homologous exon substitutions, both in the human proteomics experiments and in parallel
analyses carried out with mouse [24]. Sixty of the 282 events that were detected in the human
study [18_TD$DIFF] (Box 5) were generated from homologous exons, a number that was substantially greaterBox 5. Genes with Strong Evidence for Alternative Splice Isoforms
Analysis of the alternative isoforms identiﬁed in large-scale proteomics experiments [24] shows that many of them are well
characterized in the literature, appear in certain cellular processes, are conserved in distant species, or are generated
from small changes in amino acid sequence. Many of the splice isoforms are detected across multiple proteomics studies
and/or in different species.
High-throughput proteomics studies would be expected to detect peptide evidence for speciﬁc splice isoforms from the
following genes. A proteomics study that did not detect splice isoforms for a high proportion of these genes would be
exceptional.
Well-studied splice variants: Prelamin-A/C (LMNAy), pyruvate kinase (PKMy), actinins (ACTN1y, ACTN4y), micro-
tubule-associated protein tau (MAPT), dystrophin (DMD), cyclin-dependent kinase inhibitor 2A (CDKN2A)
Themost highly expressed splice variants: LAP2alpha (TMPO), inhibitor of nuclear factor kappa-B kinase-interacting
protein (IKBIPy), plectin (PLECz), tropomyosins (TPM1yz, TPM3yz, TPM4y), pyruvate kinase (PKMy), glutaminase kidney
isoform (GLS), ﬁbulin 1 (FBLN1y)
Highly conserved splice variants: plasma membrane calcium-transporting ATPases (ATP2B1y, ATP2B4y), mannan-
binding lectin serine protease 1 (MASP1y), LIM domain-binding protein 3 (LDB3yz)
Splice isoforms that swap one set of Pfam domains for another: nebulin (NEBL), homeobox protein cut-like 1
(CUX1), dystonin (DST)
Splice variants linked to disease: cyclin-dependent kinase inhibitor 2A (CDKN2A), annexin A6 (ANXA6), calumenin
(CALUy), cell division control protein 42 homolog (CDC42y), pyruvate kinase (PKMy)
Heart and skeletal muscle-speciﬁc splice isoforms: LIM domain-binding protein 3 (LDB3)yz, tropomyosins
(TPM1yz, TPM2yz), titin (TTNy), PDZ and LIM domain protein 5 (PDLIM5), PDZ and LIM domain protein 3 (PDLIM3y)
Splicing factors: splicing factor 1 (SF1), heterogeneous nuclear ribonucleoproteins (HNRNPC, HNRNPD, HNRNPK,
HNRNPR), polypyrimidine tract-binding protein 2 (PTBP2), poly(U)-binding-splicing factor PUF60 (PUF60)
Splicing variants generated from tandem alternative splice sites [48]: drebrin-like protein (DBNL), cellular nucleic
acid-binding protein (CNBP), [2_TD$DIFF] eukaryotic initiation factor 2B subunit delta (EIF2B4), heterogeneous nuclear ribonucleo-
protein (HNRNPR)
y
[12_TD$DIFF]Splice variant generated from homologous exons.
zMore than one distinct variant detected for this gene.
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proteomics analysis, compared with just 0.01% of other annotated splice events). Analysis
of other studies backs this up: proteomics studies detect a high proportion of alternative
isoforms generated by swapping one homologous exon for another [28–31].
There was evidence for all 60 homologous substitutions in the genomes of bony ﬁsh, suggesting
that all these splice events had ancient origins, evolving at least 460 million years ago. While
alternative isoforms generated from homologous exons were highly conserved, [5_TD$DIFF] just 19% of
alternative exons annotated in the human reference set [19_TD$DIFF]are conserved in mouse [24].
These homologous exon splice events will have only subtle effects on structure and function
(Figure 3). One way of measuring the effect on structure and function is to analyze the(A)
(B)
Figure 3. Solved Crystal Structures for Two Pairs of Mass Spectrometry-Detected Alternative Isoforms.
Solved protein structures for alternative isoforms that differ by substitution of homologous exons. In each ﬁgure, one isoform
is colored orange and the other blue. The region coded by the homologous exons is shown in light blue and light orange. (A)
Pyruvate kinase isoforms M1 and M2 [46]; those residues that differ in the alternative isoform are shown as sticks. The two
structures (PDB codes 1srf and 1srd) are practically identical, the largest differences are in a loop from the substituted
region (bottom right) and in the loop region [7_TD$DIFF]where the M2 isoform binds the fructose biphosphate substrate and the
M1 isoform does not (top right). (B) ‘Central’ and ‘peripheral’ isoforms of ketohexokinase [47]. Both isoforms bind
the substrate fructose; the homologous exon substitution affects the substrate-binding site; the two residues that differ
in the site are shown as blue and gray sticks. The peripheral isoform does not bind fructose as strongly as the central
isoform; the change in binding residues may mean that the peripheral isoform has a different substrate.
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Alternative isoforms identiﬁed in the proteomics experiments were highly enriched in splice
events that did not affect Pfam functional domain composition. Only 15% of the alternative splice
events would damage or cause the loss of a Pfam domain, whereas 68% of the annotated
alternative splice events in CDS regions would break or cause the loss of one or more Pfam
domains.
The preservation of functional domains, the enrichment in homologous exon substitutions, and
the cross-species conservation clearly demonstrate that alternative isoforms with the most
conservative changes tend to be the most prevalent in the cell.
Most Alternative Exons Are Not Under Selective Pressure
Most annotated alternative isoforms are not supported by proteomics evidence and have limited
cross-species conservation. However, these isoforms may be lineage-speciﬁc innovations [10].
Variation within human populations could provide support for this hypothesis; if recently evolved
exons code for functionally relevant proteins, then they should be evolving under purifying
selection.
A recent analysis of data from healthy patients in the 1000 genomes project [ [20_TD$DIFF]50] demonstrated
that alternative exons from the reference annotation had proportionally more predicted high-
impact variants than the APPRIS principal isoforms [49]. This result indicates that alternative
exons are under weaker purifying selection than the APPRIS principal isoforms.
Our own in-house investigation of the same data supports these results. Exons from APPRIS
principal isoforms have a substantially lower proportion of high-impact variants than exons from
alternative isoforms (Figure 4). Not only are alternative exons evolving under weaker purifying
selection, but also the patterns observed for rare and common variants suggest that most0.12
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Figure 4. Genome-wide Distribution of Sequence Variants in Principal and Alternative Isoforms. (A) The ratio of
nonsynonymous to synonymous variants and (B) the percentage of high-impact variants shown for three sets of protein-
coding sites: alternative, those sites that fall inside exons belonging exclusively to alternative variants (895 887 sites in total);
APPRIS, those sites from exons that code for APPRIS main isoforms [37] and not for alternative isoforms (4 732 523 sites);
and intersection, those sites that fall inside exons that code for both alternative variants and APPRIS main isoforms (10 792
735 sites). Each ratio was calculated for both rare and common allele frequencies identiﬁed from Phase 3 of the 1000
Genomes project [50] (the boundary between rare and common was set at an allele count of 25, corresponding to an allele
frequency of 0.005). High-impact variants deﬁned by Variant Effect Predictor [51] were splice acceptor variants, splice donor
variants, stop gains, stop losses, and frameshift variants.
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Outstanding Questions
Why is there so little evidence for
the translation of alternative splice
isoforms?
What cellular quality controls are
involved in the translation of alternative
isoforms?
What proportion of alternative isoforms
are actually translated as stable
proteins?
What is the cellular role of those splice
isoforms that are detected in proteo-
mics experiments?alternative exons evolve neutrally; even though alternative sites represented only 5% of our data,
they contributed 29% of the high-impact variants across all allele frequencies and 57% of high-
impact variants for the most common allele frequencies.
The fact that exons from alternative isoforms have a substantially greater proportion of high-
impact and missense variants shows that most alternative isoforms are not under selective
pressure. This underscores the importance of the main protein isoforms and suggests that most
alternative isoforms, if translated, will have little or no functional relevance as proteins.
Concluding Remarks
Alternative splicing is well documented at the transcript level, and microarray and RNA-seq
experiments routinely detect evidence for many thousands of splice variants. However, large-
scale proteomics experiments identify few alternative isoforms. The gap between the numbers of
alternative variants detected in large-scale transcriptomics experiments and proteomics anal-
yses is real and is difﬁcult to explain away as a purely technical phenomenon. While alternative
splicing clearly does contribute to the cellular proteome, the proteomics evidence indicates that it
is not as widespread a phenomenon as suggested by transcript data. In particular, the popular
view that alternative splicing can somehow compensate for the perceived lack of complexity in
the human proteome [9,17] is manifestly wrong.
Those isoforms detected in proteomics experiments are highly conserved and signiﬁcantly
enriched in mutually exclusively spliced homologous exons and subtle splice events that do not
disrupt functional domains. This is highly suggestive of a model in which splice isoforms with
small variations can more easily gain a functional role in the cell, and in which those alternative
isoforms with changes leading to loss of structure and function (such as the damage or loss of a
functional domain) are less likely to acquire functional importance.
What happens to alternative transcripts that are not translated in detectable quantities is not
clear. Some may be expressed in small quantities, in limited tissues, or under special circum-
stances, some may be regulated by cellular quality-control pathways [52,53], ensuring that
isoforms with damaged domains are not present in the cell, and some may have functions other
than generating a protein product [54]. Resolving the fate of these missing isoforms will be of
great importance to help understand the cellular machinery.
The agreement between the main experimental proteomics isoform, the CCDS variants from
genomic information, and the APPRIS principal isoforms from conservation demonstrates that
the vast majority of genes have a single dominant splice isoform. The fact that the main isoforms
detected at the protein level agree with the APPRIS principal isoforms is an important detail,
because it means that dominant cellular isoforms can be predicted for any well-annotated
genome.
The importance of this main cellular isoform, especially in large-scale experiments and biomedi-
cal applications, can be appreciated from the remarkable results from the variant calling
experiments (Figure 4). These results show that most alternative exons are evolving neutrally,
suggesting that most alternative splice events are not evolutionary innovations. Of course, this
also suggests that many alternative transcripts will not be translated into functional proteins.
This has important practical implications for predicting the effect of genetic variants. High-impact
variants are usually the most interesting in clinical studies, but they are also the variants most
enriched in false positives [55] and those that most frequently associate to alternative transcripts.
Variant effects should be predicted for main isoforms rather than, as frequently done, choosing
the transcript with the highest predicted impact.Trends in Biochemical Sciences, Month Year, Vol. xx, No. yy 11
TIBS 1293 No. of Pages 13The results from large-scale proteomics experiments [24,36] are in line with evidence from
cross-species conservation [24], human population variation studies [49], and investigations into
the relative effect of gene expression and alternative splicing [19,22]. Gene expression levels, not
alternative splicing, seem to be the key to tissue speciﬁcity [19]. While a small number of
alternative isoforms are conserved across species, have strong tissue dependence, and are
translated in detectable quantities, most have variable tissue speciﬁcities and appear to be
evolving neutrally. This suggests that most annotated alternative variants are unlikely to have a
functional cellular role as proteins (see Outstanding Questions).
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